Mantle Cell Lymphoma Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape, and ASH 2023 Updates | Roche, AbbVie, BeiGene, Eli Lilly, Genentech, Incyte, Janssen, Newave, Nurix, Takeda

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 35+ key pharma and biotech companies are working on 35+ pipeline drugs in the Mantle Cell Lymphoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Mantle Cell Lymphoma Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Mantle Cell Lymphoma Therapeutics Market.

The report provides a detailed description of the Mantle Cell Lymphoma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Mantle Cell Lymphoma Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/mantle-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Mantle Cell Lymphoma Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Mantle Cell Lymphoma therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mantle Cell Lymphoma treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Mantle Cell Lymphoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Mantle Cell Lymphoma treatment market.

Learn More about the Clinical and Commercial Development Activities in the Mantle Cell Lymphoma Therapeutics Domain @
https://www.delveinsight.com/report-store/mantle-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Mantle Cell Lymphoma (MCL) Therapeutics Analysis
The current treatment strategies for Mantle Cell Lymphoma primarily depend on multiple factors, including the stage of the disease, the age of the patient, and the patient's overall health. Mantle Cell Lymphoma is usually diagnosed once it has spread throughout the body, and the majority of these patients require treatment. While Mantle Cell Lymphoma is considered a difficult cancer to treat, tremendous progress has been made in the discovery of new treatments for the disease. In general, the currently recommended mainstays for this specific cancer ailment include Active Surveillance, Chemotherapy, Targeted therapy, and Transplantation.

To improve the treatment outlook, several major pharma and biotech companies are developing therapies for Mantle Cell Lymphoma. Currently, Abbvie is leading the therapeutics market with its Mantle Cell Lymphoma drug candidates in the most advanced stage of clinical development.

The dynamics of the Mantle Cell Lymphoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period.

Key Developments in the Mantle Cell Lymphoma Market
• On Jan. 27, 2023, Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), announced that the U.S. Food and Drug Administration (FDA) approved Jaypirca™ (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. Jaypirca was approved under the FDA's Accelerated Approval pathway based on the response rate from the open-label, single-arm, international, Phase 1/2 study, called the BRUIN trial.
• On June 14, 2023, Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced the presentation of clinical and preclinical data from its targeted protein degradation programs, NX-5948 and NX-2127, which are being evaluated in ongoing Phase 1 clinical trial in patients with relapsed/refractory B cell malignancies. These data are being presented at the 17th International Conference on Malignant Lymphoma (ICML) which is being held June 13-17, in Lugano, Switzerland.
• KTE-X19( tecartus) was approved in the US and Europe in 2020. It is currently only used to treat Mantle Cell Lymphoma, which is not on the approved indications of any of the other CAR-Ts. In January 2020, the European Medicines Agency (EMA) validated Gilead's marketing authorization application (MAA) for KTE-X19 or the treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma. In July 2020, the US FDA approved Tecartus for patients with Mantle Cell Lymphoma that does not respond to other treatments or have recurred.

Mantle Cell Lymphoma Companies in the Therapeutics Market Include:
• Juno Therapeutics
• AbbVie
• BeiGene
• Eli Lilly and Company
• Genentech
• Incyte Corporation
• Janssen Biotech
• Newave Pharmaceutical
• Nurix
• Roche
• Starton Therapeutics
• Takeda Oncology
• TG Therapeutics
And Many Others

Emerging and Marketed Mantle Cell Lymphoma Therapies Covered in the Report Include:
• Venetoclax: AbbVie
• Daratumumab: Janssen Pharmaceutical
• NVG-111: Novalgen
• HMPL-760: Hutchison medipharma
• Orelabrutinib: Beijing InnoCare Pharma Tech
• LOXO-338: Eli Lilly and Company
And Many Others

Get an in-depth Assessment of the Emerging Therapies and Mantle Cell Lymphoma Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Mantle Cell Lymphoma Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Mantle Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous

Molecule Type
Products have been categorized under various Molecule types such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Mantle Cell Lymphoma Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Mantle Cell Lymphoma Current Treatment Patterns
4. Mantle Cell Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Mantle Cell Lymphoma Late-Stage Products (Phase-III)
7. Mantle Cell Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Mantle Cell Lymphoma Discontinued Products
13. Mantle Cell Lymphoma Product Profiles
14. Mantle Cell Lymphoma Companies
15. Mantle Cell Lymphoma Drugs
16. Dormant and Discontinued Products
17. Mantle Cell Lymphoma Unmet Needs
18. Mantle Cell Lymphoma Future Perspectives
19. Mantle Cell Lymphoma Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.